Growth factors and myostatin inhibitors
Arkham Labs editorial/Published 8 September 2026/Revised 12 September 2026/Corrections policy
Insulin-like growth factor analogues, mechano growth factor variants and follistatin. Every compound in this family is graded Preclinical, and one of them carries that grade as a floor rather than a finding — there is no study of PEG-MGF at any level, in any system.
This is the only family in the library where not one compound has a published human study of any kind. Across five guides and ninety-two references, the count of human subjects is zero.
The one exception proves the shape of it. The only human data on injected follistatin is an adverse-event report: eleven cases of central serous chorioretinopathy following subcutaneous injection. The family’s human record consists of harm, not benefit. PEG-MGF is graded Preclinical as a floor rather than a finding — five indexed records, none of them a study of the compound, and no in vitro work either. It holds the lowest grade in the system because there is nothing lower.
- Guides in this family
- 5
- Peer-reviewed sources
- 92
- Grades represented
- Preclinical 5
- Follistatin 344◦Preclinical
- IGF-1 DES◦Preclinical
- IGF-1 LR3◦Preclinical
- MGF◦Preclinical
- PEG-MGF◦PreclinicalFloor
The only family in which not one compound has a published human study of any kind. If a single fact about this category deserves to be better known, it is this one.
For laboratory research use only. Not for human consumption. Nothing here is medical advice.